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Abstract
We have recently described a new form of light chain deposition disease (LCDD) presenting as a severe cystic lung disorder requiring
lung transplantation. There was no bone marrow plasma cell proliferation. Because of the absence of disease recurrence after bilateral
lung transplantation and of serum free light chain ratio normalization after the procedure, we hypothesized that monoclonal light chain
synthesis occurred within the lung. The aim of this study was to look for the monoclonal B-cell component in three patients with cystic
lung LCDD. Histological examination of the explanted lungs showed diffuse non-amyloid  light chain deposits associated with a mild
lymphoid infiltrate composed of aggregates of small CD20 , CD5, CD10 B lymphocytes reminiscent of bronchus-associated lymphoid+
tissue. Using PCR, we identified a dominant B-cell clone in the lung in the three studied patients. The clonal expansion of each patient
shared a unmutated antigen receptor variable region sequence characterized by the use of IGHV4-34 and IGKV1 subgroups with heavy
and light chain CDR3 sequences of more than 80  amino acid identity, a feature evocative of an antigen-driven process. Combined with%
clinical and biological data, our results strongly argue for a new antigen-driven primary pulmonary lymphoproliferative disorder.
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INTRODUCTION
Monoclonal immunoglobulin (IG) synthesis characterizes monoclonal gammopathies that result from a clonal proliferation of B
lymphocytes. The monoclonal component may be directly pathogenic particularly through its high serum concentration, its abnormal structure
or its antibody activity leading to several manifestations or affections including tissular deposits most often composed of immunoglobulin light
chain subunits. Light chain deposition is responsible for light-chain amyloidosis and light chain deposition disease (LCDD), the term LCDD
being restricted to the non-amyloid form of these deposits. LCDD, described by Randall in 1976   is a systemic multivisceral disorder with a1 ,
constant renal involvement . Apart from the kidneys, the heart and liver are the most frequently concerned organs . Lung involvement is2–7 2–7
asymptomatic and usually diagnosed at the time of autopsy by systematic immunofluorescence (IF) study. In 1987, non-amyloid nodular light
chain deposits restricted to the lung have been described and recognized as an new LCDD clinicopathological entity . The nodules were8–13
usually an incidental radiological finding. They may be single or multiple and ranged in size from 0.7 to 4 cm. In 2006, we have reported in
three patients a new clinicopathological presentation named cystic lung LCDD . The patients had dyspnea and numerous cysts distributed in14
both lungs on the CT scan. Unlike systemic LCDD, they progressively developed end-stage respiratory failure requiring lung transplantation.
Lung transplantation was bilateral in all cases. Moreover, none of the patients had renal disturbances and the origin of light chain production
was not found by bone marrow biopsy and aspiration. Histological examination of the lung explant specimens showed diffuse parenchymal
non-amyloid monoclonal  light chain deposits associated with numerous cysts and a mild lymphoplasmacytic infiltrate. Despite the lack ofκ
morphological criteria for a pulmonary B cell neoplasm, the normalization of serum free light chains /  ratio after bilateral lung transplantationκ λ
and the absence of recurrence of the disease several years after the procedure lead us to speculate that B-cell clonal expansion was localized
within the lung. Therefore, we design the present study in order to look for the monoclonal B-cell component.
Using PCR, we identified a dominant B-cell clone in the lung of the three studied patients without peripheral blood involvement.
Furthermore, we showed that each patient s specific clonal expansion shared an unmutated IGHV4-34/IGKV1 receptor. Combined with clinical’
and biological observations, our data strongly suggest that cystic lung LCDD is a new antigen-driven primary pulmonary lymphoproliferative
disorder.
PATIENTS AND METHODS
Patients (see )Table 1
Among the 572 patients who underwent lung transplantation at Beaujon (Clichy) and Foch (Suresnes) Hospitals, France, 36 had a
pulmonary cystic disorder. Of them, three fulfilled the diagnostic criteria of cystic lung LCDD . The diagnosis of LCDD was made before14
lung transplantation in only one patient (patient 2) on a surgical lung biopsy. For the two other patients, it was established on the explanted
lungs.
Diagnosis of LCDD
Histological examination of lung specimens showed similar lesions that has been previously described . Briefly, the main finding was14
the presence of non-amyloid amorphous eosinophilic deposits composed of monotypic  light chains widely infiltrating alveolar walls, smallκ
airways and vessels. Congo red did not show apple-green birefringence under polarized light and electron microscopy revealed granular
electron-dense deposits, thus excluding amyloidosis. The k light chain nature of the deposits was determined by immunofluorescence study on
frozen tissue sections. , IgG, IgA and IgM were not detected. The deposits were surrounded by macrophagic giant cells and were associatedλ
with cystic lung destruction characterized by emphysematous-like changes and marked bronchiolar dilatation. Only small preserved lung areas
were found. A mild lymphoplasmacytic infiltrate was present in the lung parenchyma and is further characterized in the present study.
Clinical presentation
Clinical characteristics of the patients are given in . Two of them (patients 1 and 2) have already been reported . Briefly, theTable 1 14
patients presented with a progressive obstructive dyspnea and numerous cysts diffusely distributed in both lungs on the CT scan. In one of
them, small bilateral hilar lymphadenopathies appeared during the follow-up (patient 1). End-stage respiratory failure reached over a period
from 3 to 10 years required lung transplantation which was bilateral in all cases. Before lung transplantation, one patient (patient 2) underwent
high dose chemotherapy followed by autologous blood stem cell transplantation as proposed in severe systemic LCDD. However the disease
persisted with worsening of dyspnea and dramatic increase in the number of cysts.
Hematological characteristics ( )Table 1
In the serum, only a free monoclonal  light chain was detected in one patient (patient 1). Bone marrow biopsy and bone marrow aspirationκ
did not show increase in the number of plasma cells or lymphocytes. Moreover, plasma cells did not show cytological abnormalities and the /κ λ
ratio was preserved.
Systemic extension of the disease ( )Table 1
Investigations for systemic extension of the disease especially including renal, liver and heart investigations, only revealed monotypic κ
light chain deposits in the salivary glands of patients 2 and 3.
Outcome
The free  light chain present before lung transplantation in patient 1 was no more identified 3 months after the procedure. The threeκ
patients are still alive without recurrence of the disease 47 months (range: 33 to 69 months) after lung transplantation.
Histological and immunohistochemical evaluation of the lymphoplasmacytic infiltrate
Explanted Lung tissue was taken from the upper, middle and lower lobes. Hilar and lobar lymph nodes were also sampled at time of
transplantation. At least 20 paraffin-embedded tissue blocks were available for each case as well as 3 lung frozen samples. Immunophenotyping
of the lymphoid population was performed on paraffin-embedded contiguous sections on Ventana Benchmark automated immunostainer with
commercial primary antibodies directed against CD20 (Dako, Denmark, clone L26, 1/500), CDS (Novocastra, UK, clone 4C7, 1/40), CD10
(Novocastra, UK, clone 56C6, 1/10), CD138 (Dako, Denmark, clone MI15, 1/200), Bcl2 (Dako, Denmark, clone 124, 1/10), IgD (Dako,
Denmark, polyclonal A0093. 1/50), CD23 (Novocastra, UK, clone 1B12, 1/40) and Ki-67 (Dako, Denmark, clone MIB-1, 1/150). IF on
deparaffined sections was performed to identify  or , light chains (Dako, Denmark, polyclonal, 1/50) within the cytoplasm of plasma cells.κ λ
DNA extraction and clonality analysis
DNA was obtained by a standard proteinase K digestion and a phenol-chloroform extraction of lung explant specimens, regional lymph
nodes and post-lung transplant peripheral blood samples after isolation of mononuclear cells on Ficoll gradient. When extracted from tissue
samples, DNA was submitted to a quality control: DNA was amplified using a multiplex PCR generating 100/200/300/400 and 600 base pairs
PCR fragments as reported . The DNA quality was scored as good when 4 or 5 bands were obtained, correct when 3 bands were obtained15
and insufficient for full clonality analysis when less than 3 bands were obtained. For immunoglobulin heavy chain gene rearrangement study,
the two PCR FR1 and FR2 were performed according to BIOMED-2 protocol . The third PCR, FR3, was done as previously described .16 17
Owing to the expected size range of FR1-JH (310 360 base pairs). FR2-JH (250 295 base pairs) and FR3-JH (75 140 base pairs) PCR– – –
products, the interpretation of PCR results was, as expected, directly related to the maximum size amplified by the sample in the control gene
PCR. For heavy chain CDR3 length diversity analysis, the amplified products were run on an ABI prism 3100 genetic Analyzer (Applied
Biosystems). Results were analyzed using Genscan analysis software (Applied Biosystems). Samples with a unique dominant peak within the
polyclonal background were considered as clonal and the clonal population was characterized by its heavy chain CDR3 size. The B-cell
repertoire pattern in pulmonary tissue sample was compared with that in blood sample and in hilar lymph node tissue sample when available. In
a patient, two dominant B-cell populations were considered identical when they displayed the same heavy chain CDR3 size. For kappa light
chain gene rearrangement analysis, BIOMED-2 protocol was used, and PCR products were electrophoresed in an 8  polyacrylamide gel after%
heteroduplex formation.15
As recommended by the French governmental Agence Nationale d Accr ditation et d Evaluation en Sant  (ANAES) in its ’ é ’ é “
Recommendations for cryopreserved cell and tissue libraries for molecular analyses  patients were informed that part of the specimens could be”
used for molecular analysis provided that all routine examinations have been performed (
).http://www.anaes.fr/ANAES/SiteWeb.nsf/wRubriquesID/APEH-3ZMHJP
Sequence analysis
For nucleotide sequence analysis, PCR products were directly sequenced (for Heavy chain genes sequencing) or strong dominant PCR
products were extracted from 6  polyacrylamide gel by elution (for Light chain genes sequencing). Big Dye Terminator cycle sequencing%
reaction kit (Applied Biosystems) was used prior to electrophoresis on an automated sequencer (ABI PRISM 3130XL, Applied Biosystems).
The sequences were aligned to Immunoglobulin sequences using IMGT/V-QUEST  and IMGT/JunctionAnalysis , from IMGT , the18 19 ®
international ImMunoGeneTics information system  ( ; founder and director Marie-Paule Lefranc, Montpellier, France ).® http://imgt.cines.fr 20
IGHV/IGHD/IGHJ or IGKV/IGKJ usage was determined and the heavy or light CDR3 were identified. Somatic mutations were defined as
nucleotide substitutions after elimination of the known polymorphisms described in IMGT . The ability to code for functional chains was®
determined by translating DNA sequences into amino acids.
FISH studies
Interphase fluorescence in situ hybridization (FISH) analyses were performed on formalin-fixed paraffin embedded tissue sections from
lung tissue specimens using split-signal DNA probes for  (Dako, SA, Glostrup, Denmark) according to the manufacturer sMALT1 ’
recommendations ( ).www.euro-fish.org
RESULTS
Non-amyloid monotypic kappa light chain deposits are associated with a lymphoplasmacytic infiltrate
The density of the lymphoplasmacytic infiltrate was variable among the 3 patients but remained mild and non destructive in all cases. Very
scarce lymphoid aggregates were present along the bronchovascular bundles in patients 2 and 3 while lymphoid aggregates were more
numerous in patient 1 ( ). Rare lymphoid aggregates displayed features reminiscent of lymphoid follicles with atrophic germinalFigure 1A
centres. Cytologically. the lymphoid cells were small, with scanty cytoplasm, round nuclei and mild plasmacytoid differentiation. There was no
large cell component. Immunohistochemical analysis showed that the lymphoid cells displayed a CD20 . CD5 . CD10 . Bcl2 . CD23 . IgD-+ − − + −
phenotype ( ) and were associated with numerous reactive CD5  T cells ( ). These lymphoid cells did not react with  and Figure 1B + Figure 1C κ λ
light chains antibodies. Rare lymphoid follicles were associated with a CD23  follicular dendritic cells meshwork. Less than 5  of these+ %
lymphocytes were labeled by anti-Ki-67 antibody ( ). In addition, scattered mature plasma cells expressing CD138 were observedFigure 1D
around the lymphoid aggregates ( ), or at distance admixed with light chain deposition. Immunofluorescence analysis with  and ,Figure 1E κ λ
light chain antibodies of this plasma cell component did not show any light chain restriction ( ).Figure 1F
The hilar and lobar lymph node architecture was preserved. The cortex and medulla were infiltrated by some  light chain deposits and aκ
mild plasma cell infiltrate without cytological abnormalities.  and  light chains were equally expressed by the plasma cells.κ λ
Examination of the salivary glands containing  light chain deposits (patients 2 and 3) only disclosed a minimal lymphoplasmacyticκ
infiltrate with similar morphological and immunophenotypical features as observed in the lung. There were occasional plasma cells that did not
show light chain restriction.
Finally, the pulmonary, nodal and salivary gland infiltrate did not exhibit the characteristic morphological criteria of MALT lymphoma, i.e.
hyperplastic reactive lymphoid follicles, expansion of the marginal zone by centrocyte-like tumor cells and lymphoepithelial lesions. The
pulmonary lymphoid infiltrate was reminiscent of bronchus-associated lymphoid tissue (BALT) .21
All three patients present a lung monoclonal B cell population
DNAs extracted from biopsies were analyzed for their amplificability. Indeed, poor DNA quality could lead to false-positive results due to
misinterpretation of pseudoclonality . All DNA has excellent or correct quality control in agreement with data currently observed from15
frozen or formalin-fixed samples .15
A dominant B-cell clone was identified in the lung tissue of the three patients. According to the DNA quality, the dominant clone was
detected with FR1, FR2 and FR3 PCR (patients 1 and 3, see ) or by one PCR (FR2) for patient 2. As shown in , this B cellfigure 2A figure 2
clone was largely predominant when compared to the surrounding normal B cells. For patients 1 and 3, hilar lymph nodes could be analyzed. In
each case, a faint dominant B-cell clone was found. It was identical to the pulmonary dominant clone ( ).figure 2B
Post-lung transplant peripheral blood B-cell repertoire was polyclonal in patients 2 and 3 ( ). Because neither lung transplantationFigure 2C
nor immunosuppressive associated therapy are supposed to cure a leukemic form of small B-cell lymphoproliferative disorder, we conclude
that lung clonal B cell detection was not related to contaminant circulating tumoral cells. In patient 1, peripheral blood B-cell repertoire
analysis was not conclusive because of deep B lymphocyte depletion.
All three clonal populations carry an unmutated IGHV4-34/IGKV1 stereotyped receptor
To further characterize these clonal populations we decided to sequence the IGH clonal rearrangement to look for somatic mutations, an
indirect criteria for antigen driven B-cell expansion . As expected from Genscan analysis, a clear dominant sequence was obtained by direct22
sequencing of PCR products (data not shown). Patients shared a common IGHV4-34 01 and IGHJ4 02 gene usage. IGHD4 23 01 gene was* * – *
also common to patients 2 and 3 ( ). Interestingly, no deletion of the 3 V-region, no N1 region was observed in the three patients. TheFigure 3 A ′
N2 region was restricted to two nucleotides (patients 1 and 3) and was absent in patient 2. However, although the N diversity was restricted, it
clearly differed between patients, avoiding PCR contamination. Surprisingly, all three IGVH genes were found unmutated.
Nucleotide sequence translation revealed not only an uncommon short 9 amino acid heavy chain CDR3 length but also an only one amino
acid divergence between patients ( ). It is interesting to note in patient 3, the usage of a different IGHD gene (IGHD5 12 01, insteadFigure 3 B – *
of IGHD4 23 01 in the other two patients) which, however, encodes the same amino acid motif YGG as a results of two mutations. The CDR3– *
comprises two charged amino acids, the basic arginine (R 106) (from the 3 V-REGION) and the acidic aspartic acid (D 116) (from the 5′ ′
J-REGION). The tip of the CDR3 loop which corresponds to the D-REGION is occupied by a tyrosine, two glycine and the amino acid 115
which results from the D J rearrangement and is the only amino acid which differs (P1: serine, small and neutral, P2: asparagine, small and–
hydrophilic, valine, medium size and hydrophobic). Those CDR3 sequences were compared to the 7.268 in frame IGH VDJ sequences of the
IMGT/LIGM-DB database and to our 10 previously published clonal pulmonary MALT Ivmphomas IGH VDJ sequences  which has been17
further extended by Bende  . No similar junctions either for length or for motive were found.et al 23
To further look for a closely homologous ( stereotyped ) receptor, as described in chronic lymphocytic leukemia CLL , , we analyzed “ ” 24 25 κ
light chain gene rearrangements. Sequence analysis in patients 2 and 3 showed the quite similar amino acid CDR3 sequences CQQY SYP TFN L
and CQQY SYP TF, respectively. The 3 V-REGION of the IGKV allows identifying the sequence CQQYNSYP as being form IGKV1 16Y Q ′ –
and the sequence CQQYYSYP as being from IGKV1 8. IGKV1 16 is rearranged to IGKJ4. It is not possible due to the mutation at the V-J– –
junction to identify the IGKJ rearranged to IGKV 1 8 (IMGT Protein display, ); Light chain CDR3 sequences were of the– http://imgt.cines.fr
same length. Unfortunately, we did not have enough DNA to perform sequence analysis of the rearranged  light chain genes in patient 1.κ
The pulmonary lymphoid infiltrate did not show rearrangement of the MALT1 gene
Using FISH analysis, we did not find any rearrangement of the MALT1 gene, a chromosomal alteration commonly observed in pulmonary
mucosa-associated lymphoid tissue (MALT) lymphoma .26
DISCUSSION
Pulmonary non-amyloid light chain deposits occur in the three following forms of LCDD: the systemic multivisceral form, the pulmonary
nodular form and, as we recently suggested, the pulmonary cystic form. The current study demonstrates that cystic lung LCDD clearly differs
from the two other forms by clinical and molecular features ( ).Table 2
Cystic lung LCDD is a rare disorder , mostly arising in young females. They had dyspnea associated with an obstructive pattern and14
numerous cysts distributed in both lung fields on the CT scan. The number of cysts progressively increased with a concomitant worsening of
dyspnea that required lung transplantation after a few years. Thirty-three to 69 months after bilateral lung transplantation, the patients are in
good condition without recurrence of the disease. These clinical findings show that lung involvement in cystic lung LCDD threatens patient s’
life as opposed to what is observed in systemic LCDD and nodular lung LCDD. Moreover, patients affected by cystic lung LCDD are 25 years
younger than the others 2 13 . Besides the age of patients and pulmonary manifestations, cystic lung LCDD may be clinically distinguished[ – ]
from the systemic multivisceral form by the absence of renal involvement and of relapse after adequate organ transplantation .27
In the systemic form of LCDD, monoclonal light chains deposited in the target organs are produced by a bone marrow clonal plasma cell
proliferation as seen in monoclonal gammopathy of undetermined significance or multiple myeloma diagnosed in 17  and 58  of cases,% %
respectively . At the opposite, in the pulmonary nodular form of LCDD, monoclonal light chain synthesis seems to be a localized process 3 8–
. A diagnosis of primary pulmonary low grade B cell lymphoma (MALT lymphoma and lymphoplasmacytic lymphoma) or lung13
plasmocytoma was made in five of the ten patients reported in the literature. In the present study, bone marrow aspiration and biopsy were
normal (plasma cells <5 , preserved /  ratio). Although the pulmonary lymphoid infiltrate associated with  light chain deposits was% κ λ κ
morphologically and immunophenotypically more suggestive of BALT than B cell neoplasm, we looked for clonality of pulmonary B cells. We
hypothesized that monoclonal light chain synthesis occurred in the lung in view of the absence of recurrence of the disease after bilateral lung
transplantation and of the normalization of serum free light chains /  ratio after the procedure. PCR clonality analysis disclosed a predominantκ λ
B cell clone in the lung of our three patients. In two of them, the same clonal expansion with a lower fluorescence signal was detected in the
hilar or lobar lymph nodes. In order to exclude a tissular infiltration by a circulating disorder, we performed peripheral blood clonality analysis.
It was done after lung transplantation but we assumed that a small B cell extrapulmonary lymphoproliferative disorder would not be cured by
lung transplantation or by immunosuppressive treatment. Peripheral blood revealed a polyclonal pattern. According to the trafficking of
antibody secreting cells  and by analogy with non-disseminated pulmonary MALT lymphoma , we postulate that involvement of regional28 29
lymph nodes and distant spread to other mucosal sites in cystic lung LCDD might be related to the peculiar expression of specific adhesion
molecules and chemokine receptors by the clonal cells and did not correspond to a metastatic process. Although the morphological features
observed in our study do not met the histological diagnosis criteria of MALT lymphoma as requested in the WHO lymphoma classification ,30
we can not exclude that these cases may be part of the morphological spectrum of pulmonary MALT lymphomas.
While it is currently acknowledged in systemic multivisceral LCDD that light chains exhibit a number of somatic mutations and/or
posttraductional modifications conferring new properties to light chain protein, no study has been yet concerned with potential distinctive
heavy chain features. Remarkably, we showed that the B cell clones from our three patients expressed homologous IGHV/IGKV repertoire for
IG rearrangement using the IGHV4-34 01/IGKV1 subgroups. The usage of a IGHV4-34/IGKV1 stereotyped receptor with closely homologous*
heavy and light chain CDR3 sequences raises the possibility of a common antigen-driven selection.
A restricted IG repertoire with similar heavy and light chain CDR3 as observed in cystic lung LCDD has already been reported for
different types of B cell lymphoproliferative disorders. Several authors have found distinct sets of stereotyped B cell antigen receptors
expressed by leukemic lymphocytes in patients with CLL , , . These data are highly suggestive of a role for antigen in promoting24 25 31–35
proliferation of B cells with particular surface IG. However, the causal antigens remain to be identified. Stereotyped B cell antigen receptors
were also found in subsets of marginal zone lymphomas arising in the lymph nodes ,  and in MALT mucosa-associated lymphoid tissue ,36 37 23
.38
In marginal zone lymphomas, the possibility of antigen-driven lymphomagenesis has been demonstrated. The risk for developing MALT
lymphoma is severely increased in patients with chronic antigenic stimulation by autoantigens and/or microbial pathogens. Chronic stimulation
of the immune system induces a sustained lymphoid proliferation favoring the neoplastic transformation process . Sj gren syndrome  and39 ö 40
autoimmune Hashimoto thyroiditis  are the most frequent underlying autoimmune conditions. The list of microbial species involved in the41
development of lymphoproliferations has progressively grown and now comprises 5 distinct members: Helicobacter pylori, Campylobacter
 and hepatitis C virus (HCV), which have been associated with MALT gastric lymphoma,jejuni, Borrelia burgdorferi, Chlamydia psittaci
immunoproliferative small intestinal disease (IPSID), MALT cutaneous lymphoma, MALT ocular lymphoma, and marginal zone spleen
lymphoma, respectively. All these variants of lymphoma have the same immunophenotypical features except IPSID. The malignant cells of
IPSID secrete a monotypic truncated Ig -heavy chain lacking an associated light chain . This fact in addition to the notion of persistentα 42
antigenic stimulation leads us to draw a parallel between IPSID and cystic lung LCDD although there are no IG tissular deposits in IPSID. Of
note, therapeutic trials have demonstrated that IPSID  as well as gastric ,  and cutaneous MALT lymphomas ,  at an early stage can42 43 44 45 46
be cured with antibiotics alone. Similarly, interferon- 2b treatment in patients with splenic marginal zone lymphoma who are infected withα
HCV lead to regression of the lymphoma . Therefore, the evidence that our study provides clues for a putative common antigen in cystic47
lung LCDD is of great interest. In our patients, the search for serum anti-HCV antibodies was negative. To address the issue of the implication
of bacterial respiratory infection promoting B cell clonal expansion in cystic lung LCDD, we performed PCR amplification using universal
bacterial 16S rDNA primers and templates prepared from frozen lung tissue (data not shown). No pulmonary bacterial infection could be
detected. These are preliminary data that require further investigations.
The preferential usage of IGHV4-34 gene found in our three patients has been previously reported in several B cell lymphoproliferations,
namely CLL , marginal zone lymphoma , , , mantle cell lymphoma , Burkitt s lymphoma , , primary central nervous system31 36 48 49 50 ’ 50 51
lymphoma , and remains still controversial in large B cell lymphoma , , . IGHV4-34 encodes autoantibodies that recognize the I/i red52 50 53 54
blood cell determinants . These autoantibodies are also able to interact with other antigenic structures such as DNA, cytoskeletal proteins or55
Fc fragment of IgG (rheumatoid factor) , . They are rare in healthy individuals although IGHV4-34 gene is expressed in the repertoire of 356 57
to 6  of the normal human peripheral blood B cells , ,  suggesting an anergic state of these cells. In contrast with the majority of% 55 58 59
IGHV4-34 expressing entity cited above, the IGHV4-34 01 sequences belonging to our three patients revealed the absence of somatic*
mutations. This finding is not consistent with a classical T-cell dependant antigenic stimulation of B lymphocytes and germinal center
phenotype. However, such a result has been already observed in thymic  and salivary gland  MALT lymphomas. Moreover, some authors38 60
have established the existence of unmutated MALT lymphomas and CLL displaying isotype switching , . These data indicate that tumoral38 61
cells may arise from peculiar B cells the activation of which could implicate a T-cell independent immune response .62
In conclusion, because the patients shared unique clinical, histological and molecular features, we propose that cystic lung LCDD should
be considered as a distinct entity. Moreover, we show that the different pulmonary B cell clones use a IGHV4-34/IGKV1 stereotyped receptor,
a molecular data strongly arguing for an antigen-driven primary pulmonary lymphoproliferation. Our results could have an important
therapeutic implication since bilateral lung transplantation seems to be the only current valid therapeutic option.
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FIGURE 1
Pulmonary lymphoplasmacytic infiltrate
This low power view shows abundant eosinophilic amorphous extracellular pulmonary deposits associated with several cysts ( ). Three lymphoid*
nodules are seen and two of them are located in the vicinity of bronchioles (arrows) (A). Immunohistochemical study revealed that the nodules are
mainly composed of small CD20 positive lymphocytes (B). At the periphery, small CD5 positive cells were present (C). Less than 5  of%
lymphocytes were labeled by anti-Ki-67 antibody (D). Anti-CD138 antibody highlights the presence of plasma cells around the nodules (E). IF
performed on deparaffined sections demonstrated that plasma cells did not show light chain restriction (F).
FIGURE 2
Genscan analysis of PCR products
Amplifications of immunoglobulin heavy chain CDR3 sequences were performed using the three FR1, FR2, FR3 primer sets. PCR products were
run on a sequence analyzer and sizes were determined using a size marker (in red) and the Genscan software. The figure shows representative data
in patient 1 of (A) the dominant clone detected in the lung, (B) the PCR product alignment of lung and lymph node dominant clone, and (C) the
comparison of lung clone and polyclonal blood B cell repertoire.
FIGURE 3
Alignment of nucleotide sequences and translation of IG heavy chain CDR3
DNA extracted from lung explant specimens was amplified using the FR1/JH BIOMED-2 PCR protocol. After purification, PCR fragments were
directly sequenced.  Sequences were aligned to Immunoglobulin sequences using IMGT/V-QUEST  and IMGT/JunctionAnalysis , fromA: 18 19
IMGT  the international ImMunoGeneTics information system  (http//imgt.cines.fr). Somatic mutations were defined as nucleotide substitutions® ®
after elimination of the known polymorphisms described in the IGMT database.  The same database determines the ability of sequences to codeB:
for functional heavy chains. First line includes amino acid positions according to the IMGT unique numbering for V-DOMAIN .20
TABLE 1
Clinical characteristics of the patients.
Patient 1 Patient 2 Patient 3
Age
 - At the onset of symptoms 33 28 37
 - At the time of LT 36 39 42
Sex Female Female Female
Smoking status (Pack-years) Former smoker (1) Non smoker Former smoker (8)
Environnment or occupational exposure Not found Not found Not found
Adenopathies ( )− ( )− ( )−
Splenomegaly ( )− ( )− ( )−
Hepatomegaly ( )− ( )− ( )−
Viral status (serology):
 - HCV infection ( )− ( )− ( )−
 - HIV infection ( )− ( )− ( )−
Monoclonal IG before LT :(1)
 - Serum Free k light chain ( )− ( )−
 - Urine ( )− ND ND
Serum IgG, IgA, IgM levels Normal Normal Normal
Bone marrow plasmocytes ( )% <5 <5 <5
Renal function (serum creatinine level, ( mol/1)μ Normal (50) Normal (55) Normal (100)
Proteinuria, mg/day 70 60 200
Liver function tests Normal Normal Normal
Heart function(2) Normal Normal Normal
Extrapulmonary deposits:
 - Bone marrow ( )− ( )− ( )−
 - Salivary glands + ( )− +
 -Skin ¤ ( )− ¤
 - Duodenum ¤ ( )− ¤
 - Rectum ¤ ( )− ¤
 -Kidney ¤ ¤ ( )−
Autologous blood stem cell transplantation before LT No Yes(3) No
Follow-up (mo) 39 69 33
Monoclonal IG after LT :(1)
 -Serum ( )− ( )− ( )−
 - Urine ( )− ( )− ( )−
Recurrence of the disease No No No
( ), absent; , present; LT, lung transplantation; ND; not done; , no biopsy performed; HCV, hepatitis C virus; HIV, human immunodeficiency virus;− + ¤
 1 protein electrophoresis and immunofixation;
 2 evaluated by echocardiography and right cardiac catheterization;
 3 without improvement or stabilization.
TABLE 2
Main characteristics that distinguish the three forms of LCDD involving the lung.
Cystic lung LCDD n  4  = 14 * Systemic multivisceral LCDD n  91= 2–7 Nodular lung LCDD n  10= 8–13
Age (range), yr 29.5 (20 37)– 55 (33 80)– 58 (33 76)–
Sex ratio (M/F) 1/3 2/1 2/3
Organ involvement:
 -Lung Yes (dyspnea) Yes (asymptomatic) Yes (asymptomatic)
 - Kidney No Yes (proteinuria, renal failure) No
 -Heart No Yes (arrhythmias, heart failure) No
Cause of death Respiratory failure Renal or heart failure No death
Recurrence after adequate organ transplantation No(1) Yes(2) Not needed
Monoclonal component (serum/urine) 25  (Serum free  light chain)% κ 85  % 63 ND
Primary bone marrow plasma cell proliferation No Yes (75 ) % 3 No
Primary pulmonary lymphoproliferation Yes No Yes (50 )%
Characterization of monoclonal component:
 - Clonal V Heavy chain IGHV4-34 Not determined Not determined
 - Clonal V Light chain κ, IGKV1 κ, IGKV4 64 κ, IGKV4 11
 - Somatic mutations No Yes ,65 66 Not determined
 * , and the present study; ND, not done;
 1 bilateral lung transplantation;
 2 renal transplantation.
